Search
beremagene geperpavec-svdt (Vyjuvek)
Indications:
- treatment of wounds in patients age >= 6 months with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene
Dosage:
- beremagene geperpavec-svdt 5000000000 UNT/ML Topical Suspension [Vyjuvek]
Mechanism of action:
- Herpes-simplex type-1 (HSV-1) vector-based genetherapy
General
gene therapy
References
1 Highlights of Prescribint Information